NETWEEK-SPA
5.2.2021 20:47:07 CET | Business Wire | Press release
Netweek SpA (ntw : im ) (the “Company” or “Netweek”), listed on the MTA market, organized and managed by the Borsa Italiana, is pleased to announce that it has entered into a binding Put Option Agreement (“Agreement”) with LDA Capital Limited ("LDA “) And LDA Capital LLC (“ LDA LLC “), a global alternative investment group. The Agreement gives the Company the right to subscribe, by LDA, newly issued shares from Netweek for a maximum of 2.0 million euros. This equity commitment will be utilized at the Company’s discretion over the next 36 months to strengthen Netweek’s balance sheet and financial structure, support its digital and online expansion, and provide fresh capital as Netweek looks to emerges from the COVID-19 pandemic.
Under this agreement, Netweek has the right, but not the obligation, to draw down capital as required. The Company will control the timing and amount of capital drawn down under this Agreement. This method of fundraising provides management with a flexible financing tool and allows the Company the ability to deploy cash on an as-needed basis rather than fully diluting existing shareholders.
LDA Capital will also be given warrants to be issued for a maximum amount of 7 million common shares of Netweek at an exercise price of 0.11 euros per share, exercisable any time during the term of the Agreement. This represents a maximum value of 0.77 million euros of additional funding, equal to a 38% premium on the closing of January 8th , 2021 and 34% higher than the average of the last 30 trading days.
The CFO of Netweek SpA, Mr. Massimo Cristofori, said:
“ I am particularly proud of this agreement with a partner like LDA Capital which once again demonstrates Netweek’s ability to identify innovative capital solutions , especially in a difficult financial environment whereby institutional funding is harder to come by.
With these incremental financial flows of capital , Netweek will be in a position to grow within the digital space while strengthening its assets along the way ”
The Managing Partner of LDA Capital, Mr. Anthony Romano, said:
“The global pandemic has significantly caused a shift towards online media, seeing an increase in online news consumption, social networking, and online public services. Due to this shift to a virtual news platform from traditional newspaper, LDA sees tremendous opportunity in supporting versatile managers and growth-oriented companies like Netweek to overcome these consumer shifts and emerge as a stronger player in the publishing space.
Through our flexible capital solutions, LDA is pleased to assist an established online media group such as Netweek as it seeks to push ahead with its newly approved busines plan, as it adapts to these new online consumer demands.”
About LDA Capital
LDA Capital is a global alternative investment group with expertise in complex, cross border transactions worldwide. Our team has dedicated their careers to international & cross border transactions having collectively executed over 200 transactions in both public and private markets across 43 countries with aggregate transaction values of over US$10 billion. For more information, please visit: www.ldacap.com ; For inquires please email:info@ldacap.com .
About Netweek SpA
The Netweek Group is the Italian leading company in hyper-local information and aims to become the reference interlocutor of the small and micro enterprises of Northern Italy through an offer of calibrated and personalized means of communication.
The Netweek Group publishes 58 local edition and 40 news sites , with over 700,000 weekly readers and 30 million page views per month. For inquiries please email : investor.relations@netweek.it
View source version on businesswire.com: https://www.businesswire.com/news/home/20210205005011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
